A phase I/II study assessing Allogeneic G-NK cell therapy for cancer
Latest Information Update: 08 Feb 2021
At a glance
- Drugs Allogeneic G-natural killer cell therapy (Primary)
- Indications Cancer; Multiple myeloma
- Focus Adverse reactions; First in man; Therapeutic Use
Most Recent Events
- 03 Feb 2021 According to an Indapta Therapeutics media release, this trial is expected to begin in 2H 2021.
- 28 Oct 2020 According to a Multiple Myeloma Research Foundation media release, The Multiple Myeloma Research Foundation (MMRF) and Indapta Therapeutics announced a partnership to support this trial and this collaboration is supported with an investment in Indapta by the MMRF's venture philanthropy arm, the Myeloma Investment Fund (MIF).
- 09 Jul 2020 According to an Indapta Therapeutics media release, the company plans to initiate this study in summer 2021.